Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 6/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30091911 | 1.00 | HDAC1 (0.56) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL2277894 | 0.90 | NR1H2 (0.67) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL30301758 | 0.90 | ESR2 (0.69) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL3024823 | 0.90 | ESR2 (0.69) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL29589913 | 0.90 | NR1H2 (0.67) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL1263486 | 0.87 | ESR2 (0.59) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL13112870 | 0.86 | HDAC6 (0.51) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL20570373 | 0.86 | HDAC1 (0.54) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL8280135 | 0.86 | ESR2 (0.56) | HDAC1HDAC6HDAC8ESR2NR1H2 | |
| SCHEMBL29835137 | 0.86 | ESR2 (0.56) | HDAC1HDAC6HDAC8ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4441040-A1 | INDOLINES AS PROTAC COMPOUNDS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| WO-2023094833-A1 | INDOLINES AS PROTAC COMPOUNDS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023284651-A1 | N-(2-AMINOPHENYL)BENZAMIDE COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| EP-3390355-B1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2022-12-28 | — | — | EP | disclosed |
| WO-2021229152-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2021-11-18 | — | — | WO | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050176775-A1 | Substituted pyridinones | PHARMACIA CORPORATION | 2005-08-11 | — | — | US | disclosed |
| EP-1554243-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005018557-A2 | SUBSTITUTED PYRIDINONES | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| WO-2004037788-A1 | BICYCLIC BENZAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGAND USEFUL IN THE TREATMENT OF NEUROLOGICAL DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | HDAC1 802/4885HDAC6 1881/4885HDAC8 1793/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | HDAC1 1069/4885HDAC6 653/4885HDAC8 2157/4885 |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | HDAC1 2/4885HDAC6 3/4885HDAC8 7/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | HDAC1 2/4885HDAC6 3/4885HDAC8 7/4885 |
| US-20050176775-A1 | Substituted pyridinones | MAPK1, MAPK6, MAP3K6 | HDAC1 965/4885HDAC6 1438/4885HDAC8 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.